Intravitreal Bevacizumab Injection for the Treatment of Choroidal Neovascularization Secondary to Candida Chorioretinitis

Sang Hyup Lee; Jung Wook Lee; Yong Un Shin; Byung Ro Lee

doi:10.3341/jkos.2014.55.7.1106

Journal List > J Korean Ophthalmol Soc > v.55(7) > 1009738

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Lee, Lee, Shin, and Lee: Intravitreal Bevacizumab Injection for the Treatment of Choroidal Neovascularization Secondary to Candida Chorioretinitis

Case Report

J Korean Ophthalmol Soc 2014;55(7):1106-1110.

Published online: 30 August 2014

DOI: https://doi.org/10.3341/jkos.2014.55.7.1106

Intravitreal Bevacizumab Injection for the Treatment of Choroidal Neovascularization Secondary to Candida Chorioretinitis

Sang Hyup Lee, MD, Jung Wook Lee, MD, Yong Un Shin, MD, PhD, Byung Ro Lee, MD, PhD

Department of Ophthalmology, Hanyang University Medical Center, Hanyang University College of Medicine, Seoul, Korea

Address reprint requests to Byung Ro Lee, MD, PhD, Department of Ophthalmology, Hanyang University Medical Center, #222 Wangsimni-ro, Seongdong-gu, Seoul 133-791, Korea, Tel: 82-2-2290-8570, Fax: 82-2-2291-8517 E-mail: stynel@nate.com

Received 7 December 2013 Revised 17 February 2014 Accepted 9 June 2014

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose

To report a case of choroidal neovascularization (CNV) secondary to candida chorioretinitis initially treated with an intravitreal bevacizumab injection.

Case summary

A 50-year-old female presented at our clinic with decreased vision and metamorphopsia in her left eye of 5 days duration. She received an anti-fungal treatment 2 months prior due to the presence of endogenous candida choroiditis in both eyes. Fluorescein angiography and optical coherence tomography (OCT) revealed juxtafoveal CNV in her left eye. Three monthly intravitreal injections of bevacizumab were administered as the initial loading dosage. Her visual symptoms improved and CNV regression was observed on OCT. No recurrence or complications were observed during the 6 month follow-up.

Conclusions

Based on the present study results we suggest that intravitreal bevacizumab injection can be used to effectively treat CNV and improve visual symptoms during the treatment of juxtafoveal CNV associated with candida choroiditis.

Keywords: Bevacizumab, Candida, Choroidal neovascularization, Choroiditis, Intravitreal injection

References

1. Jampol LM, Sung J, Walker JD, et al. Choroidal neovascularization secondary to Candida albicans chorioretinitis. Am J Ophthalmol. 1996; 121:643–9.

2. Beebe WE, Kirkland C, Price J. A subretinal neovascular membrane as a complication of endogenous Candida endophthalmitis. Ann Ophthalmol. 1987; 19:207–9.

3. Tedeschi M, Varano M, Schiano Lomoriello D, et al. Photodynamic therapy outcomes in a case of macular choroidal neovascularization secondary to Candida endophthalmitis. Eur J Ophthalmol. 2007; 17:124–7.

4. CATT Research Group. Ranibizumab and bevacizumab for neo- vascular age-related macular degeneration. N Engl J Med. 2011; 364:1897–908.

5. Ruiz-Moreno JM, Montero JA. Intravitreal bevacizumab to treat myopic choroidal neovascularization: 2-year outcome. Graefes Arch Clin Exp Ophthalmol. 2010; 248:937–41.

6. Julian K, Terrada C, Fardeau C, et al. Intravitreal bevacizumab as first local treatment for uveitis-related choroidal neovascularization: long-term results. Acta Ophthalmol. 2011; 89:179–84.

7. Ehrlich R, Ciulla TA, Maturi R, et al. Intravitreal bevacizumab for choroidal neovascularization secondary to presumed ocular histoplasmosis syndrome. Retina. 2009; 29:1418–23.

8. Schadlu R, Blinder KJ, Shah GK, et al. Intravitreal bevacizumab for choroidal neovascularization in ocular histoplasmosis. Am J Ophthalmol. 2008; 145:875–8.

9. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009; 148:43–58.e1.

10. Sheu SJ. Intravitreal ranibizumab for the treatment of choroidal neovascularization secondary to endogenous endophthalmitis. Kaohsiung J Med Sci. 2009; 25:617–21.

Figure 1.

(A) A colored fundus photograph of a patient with endogenous Candida chorioretinitis showing multifocal yellow-white chorioretinal infiltrates in both the eyes. (B) Color fundus photographs after systemic anti-fungal therapy. A reduced number of multiple yellow-white infiltrates and some chorioretinal scars remained in both eyes. (C, D, E) Imaging studies of the patient who had a visual disturbance in the left eye two months after anti-fungal therapy administration. (C) Color fundus photograph showing subretinal hemorrhage and subretinal membrane temporal to the left fovea. (D) Fluorescein angiography demonstrates a late juxtafoveal leakage. (E) Subretinal fluid and a subretinal neovascular complex are visible on the spectral-domain optical coherence tomography image.

Figure 2.

(A) Color fundus and spectral-domain optical coherence tomography (OCT) images of the left eye of a patient treated with a single bevacizumab injection. Subretinal fluid and neovascular complex were not observed and only pigment epithelial detachment temporal to the fovea remained. Two additional monthly intravitreal bevacizumab injections were administered. (B) No recurrence or complications were observed on fundus photograph and OCT imaging during the eight-month follow-up.

TOOLS

Similar articles